ProCE Banner Activity

Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

Podcast Episodes

Listen to this expert overview of the most interesting findings related to the clinical use of bispecific antibody therapy for relapsed/refractory multiple myeloma that were presented at the 2024 annual American Society of Hematology meeting.

Released: February 11, 2025

Expiration: February 10, 2026

Share

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC.

ProCE Banner
ProCE Banner

Supporters

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by a grant from Pfizer Inc. Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pfizer, Inc.

Regeneron Pharmaceuticals, Inc

Faculty Disclosure

Primary Author

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD: consultant/advisor/speaker: AbbVie, Amgen, ArcellX, BD Biosciences, BeiGene, Bristol Myers Squibb, Carsgen, GlaxoSmithKline, Janssen, K36, Moderna, Pfizer, Regeneron, Roche/Genentech, Sanofi, Takeda; research (paid to institution): AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Carsgen, GlaxoSmithKline, Gracell Bio, Janssen, Oricell, Roche/Genentech, Sanofi, Takeda, Telogenomics.